Published in Hepatitis Weekly, September 23rd, 2002
U.S. Patent No. 6399654 (Biflavanoids and derivatives thereof as antiviral agents) bolsters the company's proprietary position in biflavanoids as potential antiviral drugs.
The biflavanoids are a class of compounds, derived from natural products, which have demonstrated in vitro biological activity in hepatitis B (HBV) and other viral diseases. Hepatitis B is one of the most common and serious infections in the world, with an estimated 350 million people that are chronic carriers. It is also estimated that 5% of the world...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.